一心堂药业集团股份有限公司 第六届董事会 2025 年第六次独立董事专门会议审核意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等法律、行政法规、中国证券监督管理委员会行政规章和规范性文件、深 圳证券交易所相关规则及规定以及《一心堂药业集团股份有限公司章程》等有关规 定，一心堂药业集团股份有限公司（以下简称"公司"）独立董事于 2025 年 10 月 24 日召开了第六届董事会 2025 年第六次独立董事专门会议。独立董事本着实事求 是、认真负责的态度，公平、公正、诚实信用的原则，基于独立判断的立场，对公 司第六届董事会第八次临时会议相关事项进行了认真审核，并发表审核意见如下： 一、关于推选公司第七届董事会非独立董事候选人的议案 作为独立董事，我们在认真审阅公司第七届董事会非独立董事候选人履历材料 的基础上，对此次推选公司第七届董事会非独立董事候选人相关事宜进行了认真核 查，我们认为： （本页无正文，为《一心堂药业集团股份有限公司第六届董事会 2025 年第六次独 立董事专门会议审核意见》签字页） ...

一心堂药业集团股份有限公司 重大信息内部保密制度 2025 年 10 月 27 日 | 第二章重大信息的含义和范围 | 2 | | --- | --- | | 第三章内部人员的含义及范围 | 7 | | 第四章保密制度 | 8 | | 第五章罚则 10 | | | 第六章附则 10 | | 一心堂药业集团股份有限公司 重大信息内部保密制度 第一章总则 第一条 为规范一心堂药业集团股份有限公司（以下简称"本公司"或"公司"）重大信 息内部管理，加强重大信息内部保密工作，维护投资者的合法权益，根据《中华人民共和国 公司法》、《中华人民共和国证券法》、《上市公司信息披露管理办法》、《深圳证券交易所股票 上市规则》等有关法律、法规、规范性文件和《公司章程》的有关规定，结合公司实际，制 定本制度。 第四条 董事会秘书和证券部负责证券监管机构、证券交易所、证券公司等机构及新闻 媒体、股东接待、咨询(质询)、服务工作。 第五条 证券部是公司唯一的信息披露机构。未经董事会批准同意,公司任何部门和个人 不得向外界泄露、报道、传送有关涉及公司内幕信息及信息披露内容。对外报道、传送的文 件、软(磁)盘、录音(像)带、光盘等涉及内幕 ...

一心堂药业集团股份有限公司 章程 2025 年 10 月 27 日 | A | | --- | | 第一章 总则 2 | | | --- | --- | | 第二章经营宗旨和范围 | 3 | | 第三章股份 5 | | | 第一节 股份发行 | 5 | | 第二节股份增减和回购 | 6 | | 第三节股份转让 | 7 | | 第四章股东和股东会 | 8 | | 第一节股东的一般规定 | 8 | | 第二节 控股股东和实际控制人 | 11 | | 第三节股东会的一般规定 | 12 | | 第四节股东会的召集 | 14 | | 第五节 股东会的提案与通知 | 16 | | 第六节 股东会的召开 | 17 | | 第七节股东会的表决和决议 | 20 | | 第五章董事会 | 24 | | 第一节董事的一般规定 | 24 | | 第二节 独立董事 | 27 | | 第三节董事会 | 30 | | 第四节 董事会专门委员会 | 33 | | 第六章 总裁及其他高级管理人员 | 35 | | 第七章财务会计制度、利润分配和审计 | 37 | | 第一节财务会计制度 | 37 | | 第二节 利润分配 | 38 | | 第 ...

Core Insights - The retail pharmacy industry is experiencing a significant transformation, moving away from rapid expansion to a focus on consolidation and adaptation to market pressures [1][2][4] - The aging population is creating new opportunities for retail pharmacies, with a notable increase in demand from the 50+ demographic, which now accounts for approximately 50% of sales [1][8][10] Part 01: Industry Trends - The high-growth era of retail pharmacies is coming to an end, with many companies reporting a reduction in store numbers [2][4] - In the first half of 2025, four out of six listed retail pharmacy companies reduced their store count, with notable closures at 老百姓大药房 and 一心堂 [2][3] - The overall number of retail pharmacies in China decreased by approximately 3,000 in Q1 2025, following a decline of 3,395 in Q4 2024 [3][4] Part 02: New Growth Drivers - The increasing elderly population is driving demand for both medical and health management services, particularly for chronic disease management [9][10] - Retail pharmacies must transition from being solely drug sellers to comprehensive health service providers to meet the evolving needs of the silver-haired demographic [10][24] Part 03: Strategic Pathways - Retail pharmacies are focusing on non-drug health products and services to cater to the health needs of the elderly [11][12] - Companies like 老百姓大药房 are seeing growth in non-drug sales, with a reported increase of over 9% in related revenues [12][25] - Successful expansion into non-drug categories requires precise product selection and innovative marketing strategies [15][26] Health Management Services - Retail pharmacies are developing differentiated services to build closer relationships with the elderly community [16][20] - Innovations include home health management services and community health stations that provide essential health services [21][23] - 老百姓大药房 has implemented programs like the "30-day blood pressure stabilization plan" to assist elderly patients in managing their health [23][24]

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-098 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司分别与广发银行股份有限公司昆明万宏支行及中信银行股份有限公司昆明分行 签订了《广发银行人民币结构性存款合同》和《中信银行结构性存款产 ...

Market Overview - The pharmaceutical commercial sector increased by 0.44% on October 23, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Jianfa Zhixin (301584) saw a significant rise of 20.00%, closing at 37.20 with a trading volume of 301,100 shares and a transaction value of 1.046 billion [1] - Other notable performers included: - Kaikai Industrial (600272) up 2.20% to 13.49 [1] - First Pharmaceutical (600833) up 1.97% to 14.01 [1] - Dazhenlin (603233) up 1.48% to 19.20 [1] - Yifeng Pharmacy (603939) up 1.31% to 25.44 [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 97.0483 million from institutional investors and 117 million from speculative funds, while retail investors saw a net inflow of 214 million [2] - The capital flow for key stocks showed: - Jianfa Zhixin had a net inflow of 1.22 billion from institutional investors, but a net outflow of 58.2871 million from speculative funds [3] - Kaikai Industrial had a net inflow of 15.4487 million from institutional investors, with a net outflow of 3.9622 million from speculative funds [3]

Core Viewpoint - The article highlights the challenges faced by Baiyunshan, particularly in its pharmaceutical and health segments, which are struggling with declining revenues and profits due to insufficient innovation and increased competition [8][14][35]. Financial Performance - In 2024, Baiyunshan's non-net profit decreased by 35.2% year-on-year, with a non-net profit of 2.21 billion RMB, reflecting a 5.8% decline in the first half of the year [8][9]. - The company's main business segments, particularly the Traditional Chinese Medicine (TCM) and health sectors, are underperforming, with TCM revenue down 10.4% and health revenue down 12.7% in 2024 [11][26]. - The commercial segment showed slight growth, with a revenue increase of 3.39%, but its low profit margins are insufficient to offset the overall profitability issues [12]. Industry Context - The pharmaceutical industry is undergoing a transformation, with policies such as centralized procurement and stricter compliance regulations putting pressure on companies [14]. - Despite the industry's challenges, Baiyunshan's performance decline is more severe than the industry average, indicating deeper structural issues within the company [14]. Product Performance - Baiyunshan's flagship product, "Jin Ge" (a treatment for erectile dysfunction), is facing intense competition, with over 50 companies now holding approval for similar products, leading to a 19.8% revenue decline in 2024 [17][19]. - The health segment's main product, Wanglaoji, is also struggling, with a 12.7% revenue drop in 2024, although it saw a rebound in the first half of 2025 with a 7.4% increase [26][27]. Innovation and R&D - Baiyunshan's investment in research and development is notably low, with R&D expenses amounting to only 290 million RMB, representing just 0.7% of revenue, which is insufficient to drive new growth [24]. - The lack of innovative products to replace declining sales from existing products is a significant concern for the company's future growth prospects [24].

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：002727 股票简称：一心堂 公告编号：2025-096号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会，审议通过 《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使用额度不超过人民 币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固定收益型或保本浮动收益型 理财产品、大额存单、定期存款、通知存款、协定存款等），相关额度在投资期限内任一时点的现金管 理金额(含前述投资的收益进行再投资的相关金额)不超过25亿元人民币。在上述额度内，资金可以滚动 使用，在额度范围内授权董事长具体办理实施相关事项。 一、使用部分暂时闲置自有资金进行现金管理情况 （一）本次进行现金管理基本情况 近日，公司分别与华夏银行股份有限公司昆明红塔支行及广发银行股份有限公司昆明万宏支行签订了 《华夏银行人民币单位结构性 ...

Core Insights - YXTT experienced a slight increase of 0.14% in stock price on October 20, with a trading volume of 77.65 million yuan [1] - The company reported a financing net purchase of 1.97 million yuan on the same day, with a total financing and securities balance of 215 million yuan [1] - For the first half of 2025, YXTT's revenue decreased by 4.20% year-on-year to 8.91 billion yuan, and net profit attributable to shareholders fell by 11.44% to 250 million yuan [2] Financing and Securities - On October 20, YXTT had a financing buy-in of 6.05 million yuan, with a current financing balance of 214 million yuan, representing 2.63% of the market capitalization [1] - The financing balance is below the 30th percentile level over the past year, indicating a low level of financing activity [1] - In terms of securities lending, YXTT repaid 2,900 shares and sold 1,500 shares on October 20, with a remaining securities lending balance of 75,780 yuan, also below the 40th percentile level over the past year [1] Shareholder Structure - As of June 30, 2025, YXTT had 33,900 shareholders, a decrease of 5.42% from the previous period, with an average of 11,712 circulating shares per shareholder, an increase of 5.73% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, holding 18.57 million shares, a decrease of 21.20 million shares from the previous period [3] - New entrants among the top ten shareholders include several funds from GF Securities, indicating a shift in institutional holdings [3]